Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

Transgelin Contributes to a Poor Response of Metastatic Renal Cell Carcinoma to Sunitinib Treatment

P. Bouchalova, J. Beranek, P. Lapcik, D. Potesil, J. Podhorec, A. Poprach, P. Bouchal

. 2021 ; 9 (9) : . [pub] 20210903

Language English Country Switzerland

Document type Journal Article

Persistent link   https://www.medvik.cz/link/bmc21023999

Grant support
NV19-08-00250 Ministerstvo Zdravotnictví Ceské Republiky

Renal cell carcinoma (RCC) represents about 2-3% of all cancers with over 400,000 new cases per year. Sunitinib, a vascular endothelial growth factor tyrosine kinase receptor inhibitor, has been used mainly for first-line treatment of metastatic clear-cell RCC with good or intermediate prognosis. However, about one-third of metastatic RCC patients do not respond to sunitinib, leading to disease progression. Here, we aim to find and characterize proteins associated with poor sunitinib response in a pilot proteomics study. Sixteen RCC tumors from patients responding (8) vs. non-responding (8) to sunitinib 3 months after treatment initiation were analyzed using data-independent acquisition mass spectrometry, together with their adjacent non-cancerous tissues. Proteomics analysis quantified 1996 protein groups (FDR = 0.01) and revealed 27 proteins deregulated between tumors non-responding vs. responding to sunitinib, representing a pattern of deregulated proteins potentially contributing to sunitinib resistance. Gene set enrichment analysis showed an up-regulation of epithelial-to-mesenchymal transition with transgelin as one of the most significantly abundant proteins. Transgelin expression was silenced by CRISPR/Cas9 and RNA interference, and the cells with reduced transgelin level exhibited significantly slower proliferation. Our data indicate that transgelin is an essential protein supporting RCC cell proliferation, which could contribute to intrinsic sunitinib resistance.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc21023999
003      
CZ-PrNML
005      
20240229093521.0
007      
ta
008      
211006s2021 sz f 000 0|eng||
009      
AR
024    7_
$a 10.3390/biomedicines9091145 $2 doi
035    __
$a (PubMed)34572331
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a sz
100    1_
$a Bouchalová, Pavla $u Department of Biochemistry, Faculty of Science, Masaryk University, 625 00 Brno, Czech Republic $7 xx0106729
245    10
$a Transgelin Contributes to a Poor Response of Metastatic Renal Cell Carcinoma to Sunitinib Treatment / $c P. Bouchalova, J. Beranek, P. Lapcik, D. Potesil, J. Podhorec, A. Poprach, P. Bouchal
520    9_
$a Renal cell carcinoma (RCC) represents about 2-3% of all cancers with over 400,000 new cases per year. Sunitinib, a vascular endothelial growth factor tyrosine kinase receptor inhibitor, has been used mainly for first-line treatment of metastatic clear-cell RCC with good or intermediate prognosis. However, about one-third of metastatic RCC patients do not respond to sunitinib, leading to disease progression. Here, we aim to find and characterize proteins associated with poor sunitinib response in a pilot proteomics study. Sixteen RCC tumors from patients responding (8) vs. non-responding (8) to sunitinib 3 months after treatment initiation were analyzed using data-independent acquisition mass spectrometry, together with their adjacent non-cancerous tissues. Proteomics analysis quantified 1996 protein groups (FDR = 0.01) and revealed 27 proteins deregulated between tumors non-responding vs. responding to sunitinib, representing a pattern of deregulated proteins potentially contributing to sunitinib resistance. Gene set enrichment analysis showed an up-regulation of epithelial-to-mesenchymal transition with transgelin as one of the most significantly abundant proteins. Transgelin expression was silenced by CRISPR/Cas9 and RNA interference, and the cells with reduced transgelin level exhibited significantly slower proliferation. Our data indicate that transgelin is an essential protein supporting RCC cell proliferation, which could contribute to intrinsic sunitinib resistance.
655    _2
$a časopisecké články $7 D016428
700    1_
$a Beranek, Jindrich $u Department of Biochemistry, Faculty of Science, Masaryk University, 625 00 Brno, Czech Republic
700    1_
$a Lapčík, Petr $u Department of Biochemistry, Faculty of Science, Masaryk University, 625 00 Brno, Czech Republic $7 xx0314630
700    1_
$a Potesil, David $u Proteomics Core Facility, Central European Institute of Technology, Masaryk University, 625 00 Brno, Czech Republic
700    1_
$a Podhorec, Jan $u Department of Comprehensive Cancer Care, Masaryk Memorial Cancer Institute, 656 53 Brno, Czech Republic $u Department of Comprehensive Cancer Care, Faculty of Medicine, Masaryk University, 656 53 Brno, Czech Republic
700    1_
$a Poprach, Alexandr $u Department of Comprehensive Cancer Care, Masaryk Memorial Cancer Institute, 656 53 Brno, Czech Republic $u Department of Comprehensive Cancer Care, Faculty of Medicine, Masaryk University, 656 53 Brno, Czech Republic
700    1_
$a Bouchal, Pavel $u Department of Biochemistry, Faculty of Science, Masaryk University, 625 00 Brno, Czech Republic
773    0_
$w MED00205373 $t Biomedicines $x 2227-9059 $g Roč. 9, č. 9 (2021)
856    41
$u https://pubmed.ncbi.nlm.nih.gov/34572331 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20211006 $b ABA008
991    __
$a 20240229093515 $b ABA008
999    __
$a ind $b bmc $g 1708160 $s 1144493
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2021 $b 9 $c 9 $e 20210903 $i 2227-9059 $m Biomedicines $n Biomedicines $x MED00205373
GRA    __
$a NV19-08-00250 $p Ministerstvo Zdravotnictví Ceské Republiky
LZP    __
$a Pubmed-20211006

Find record

Citation metrics

Archiving options